Regen BioPharma (RGBP) 10-Q 29 Jul 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2015	Jul. 01, 2015
Document And Entity Information
Entity Registrant Name	Regen BioPharma Inc
Entity Central Index Key	1,589,150
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		113,937,338
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Balance Sheet (Unaudited)

Balance Sheet (Unaudited) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash	$ 208,582	$ 0
Note Receivable	12,051	$ 10,422
Prepaid Expenses	6,289
Accrued Interest Receivable	1,081	$ 233
Total Current Assets	228,003	10,655
TOTAL ASSETS	228,003	10,655
Current Liabilities:
Bank Overdraft	0	6,137
Accounts payable	1,190	3,305
Notes Payable	103,751	120,169
Accrued payroll taxes	6,692	8,463
Accrued Interest	18,147	$ 2,212
Accrued Rent	5,000
Accrued Payroll	10,501
Total Current Liabilities	145,281	$ 140,286
Total Liabilities	145,281	140,286
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock, ($0.0001 par value) 500,000,000 shares authorized, 113,525,096 issued and outstanding as of June 30, 2015 and 51,907,917 shares issued and outstanding as of September 30, 2014	11,353	$ 5,191
Series A Preferred, 90,000,000 authorized and 0 authorized; 60,548,364 and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively	6,055
Series AA Preferred ($0.0001) par value 600,000 authorized and 30,000 and 0 outstanding as of June 30, 2015 and September 30, 2014 respectively	3
Additional Paid in capital	11,209,694	$ 485,097
Contributed Capital	728,658	658,658
Retained Earnings (Deficit) accumulated during the development stage	(11,873,041)	(1,278,577)
Total Stockholders' Equity (Deficit)	82,722	(129,631)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 228,003	$ 10,655

Balance Sheet (Parenthetical)

Balance Sheet (Parenthetical) - $ / shares	Jun. 30, 2015	Sep. 30, 2014
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	113,525,096	51,907,917
Common stock, shares outstanding	109,310,811	51,907,917
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, shares authorized	100,000,000	5,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001
Preferred stock, shares authorized	90,000,000	0
Preferred stock, shares issued	60,548,364	0
Preferred stock, shares outstanding	60,548,364	0
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued	30,000	0
Preferred stock, shares outstanding	30,000	0

Statement of Operations (Unaudi

Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	68,081	0	93,287	13,867
General and Administrative	463,765	127,580	906,754	389,961
Consulting and Professional Fees	73,364	30,287	413,125	109,917
Rent	16,200	0	43,071	0
Total Costs and Expenses	621,410	157,867	1,456,238	513,745
OPERATING LOSS	(621,410)	(157,867)	(1,456,238)	(513,745)
OTHER INCOME & (EXPENSES)
Interest Income	297	14	848	14
Refunds of amounts previously paid	0	490	0	490
Interest Expense	(3,512)	0	(18,742)	0
Capital contribution to parent	0	(8,658)	0	(48,510)
Loss on issuance of common shares for less than fair value	(937,425)	0	(9,116,857)	0
Preferred shares issued pursuant to contractual obligations	(321)	0	(3,475)	0
TOTAL OTHER INCOME (EXPENSE)	(940,961)	(8,154)	(9,138,226)	(48,006)
NET INCOME (LOSS)	$ (1,562,371)	$ (166,021)	$ (10,594,463)	$ (561,751)
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$ (.0141)	$ (.0032)	$ (.1333)	$ (.0152)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	110,648,054	51,909,907	79,454,728	37,082,956

Statement of Cash Flows (Unaudi

Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (10,594,463)	$ (561,751)
Adjustments to reconcile net Income to net cash
Preferred Stock issued for Expenses	100
Preferred Stock issued for interest	$ 891
Common Stock issued for expenses
Preferred Stock issued pursuant to contractual obligations	$ 3,475
Common Stock issued to Consultants	226,177
Preferred Stock issued to Consultants	440
Increase (Decrease) in Accounts Payable	(2,115)	$ 117
(Increase) Decrease in Notes Receivable	(1,629)	(2,222)
(Increase) Decrease in Interest Receivable	(848)	$ (14)
Increase (Decrease) in Bank Overdraft	(6,137)
Increase (Decrease) in Accrued Expenses	29,665	$ 7,343
(Increase) Decrease in Prepaid Expenses	(6,289)
Net Cash Provided by (Used in) Operating Activities	(10,350,734)	$ (556,527)
CASH FLOWS FROM FINANCING ACTIVITIES
Common Stock issued for Cash	0	300,000
Increase in Contributed Capital	70,000	140,000
Increase (Decrease) in Notes Payable	19,582	$ 50,000
Increase in Convertible Notes Payable	972,686
Increase in issuance of stock below fair value	9,116,857
Increase in Additional Paid in Capital	380,191
Net Cash Provided by (Used in) Financing Activities	10,559,316	$ 490,000
Net Increase (Decrease) in Cash	$ 208,582	(66,527)
Cash at Beginning of Period		115,922
Cash at End of Period	$ 208,582	$ 49,395
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	1,002,686
Preferred Shares Issued for Debt	$ 6,000

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada. The Company is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc, a Delaware corporation. The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. D. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. E. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. F. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. G. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. H. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Jun. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows. In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $ 11,873,041 during the period from April 24, 2012 (inception) through June 30, 2015. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. During the quarter ended March 31, 2015 the Company raised $775,000 through the issuance of convertible debt and during the quarter ended June 30, 2015 the Company raised $90,000 through the issuance of convertible debt ( Note 4).

Notes Payable and Convertible N

Notes Payable and Convertible Notes Payable	9 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes Payable	NOTE 4. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE June 30, 2015 September 30, 2014 Bio Matrix Scientific Group, Inc. (Note 7) 19,701 90,000 David Koos ( Notes7) 50 30,168 Bio Technology Partners Business Trust 84,000 0 Notes payable $ 103,751 $ 120,168 $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. $50 lent to the Company by David Koos. is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. $84,000 lent to the Company by Bio Technology Partners Business Trust. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. CONVERTIBLE NOTES PAYABLE During the quarter ended March 31, 2015 the Company issued Convertible Notes ( “Notes”) with an aggregate face value of $882,686 . Consideration for these Notes consisted of: (a) $775,000 cash and (b) Satisfaction of $107,686 of existing indebtedness: Each Note becomes due and payable at the demand of the Lender at any time after one year subsequent to the issuance date and bears simple interest at 10% per annum payable quarterly at the demand of the Lender. All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender. Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period. If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series “A” Stock of the Company for each share of Common Stock received through conversion. All Notes were fully converted during the quarter ended March 31, 2015. 31,539,262 common shares of Regen were issued to the Convertible Noteholders in satisfaction of the convertible indebtedness. 31,538,862 of the Company’s Series A Preferred shares were issued to Noteholders pursuant to the terms and conditions of the Notes. The Company analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $2,368,685 was recognized by the Company. This liability was eliminated prior to the end of the Company’s second quarter as a result of the full conversion of all Notes prior to the end of the Company’s second quarter. During the quarter ended June 30, 2015 the Company issued Convertible Notes ( “Notes”) with an aggregate face value of $90,000 . Consideration for these Notes consisted of $90,000. All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Or (2) $0.03 per share Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender. Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period. If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series “A” Stock of the Company for each share of Common Stock received through conversion. During the quarter ended June 30, 2015 the Company issued 3,214,285 of its common shares in satisfaction of the abovementioned convertible notes and 3,214,285 shares of its Series A Preferred stock in accordance with the terms and conditions of abovementioned convertible notes. . The Company values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $350,666 was recognized by the Company in connection with $90,000 of convertible notes payable issued during the quarter ended June 30, 2015. This liability was eliminated prior to the end of the Company’s third quarter as a result of the full conversion of these convertible noted prior to the end of the Company’s third quarter.

Notes Receivable

Notes Receivable	9 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Notes Receivable	NOTE 5. NOTES RECEIVABLE June 30, 2015 September 30, 2014 Entest Biomedical, Inc. (Note 7) $ 12,051 $ 10,422 Notes Receivable $ 12,051 $ 10,422 $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 6. INCOME TAXES As of June 30, 2015 Deferred tax assets: Net operating tax carry forwards $ 4,036,834 Other -0- Gross deferred tax assets 4,036,834 Valuation allowance (4,036,834 ) Net deferred tax assets $ -0- As of June 30, 2015 the Company has a Deferred Tax Asset of $4,036,834 completely attributable to net operating loss carry forwards of approximately $11,873,041 (which expire 20 years from the date the loss was incurred). Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0. Income tax is calculated at the 34% Federal Corporate Rate.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS As of June 30, 2015 the Company has received capital contributions from Bio Matrix Scientific Group, Inc (“BMSN”) , a corporation under common control with the Company and which possesses the majority of the voting power of the shares outstanding of the company, totaling $728,658 and has issued 50,010,000 common shares to BMSN for aggregate consideration of $20,090. The Company also utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month. As of June 30, 2015 Entest Biomedical Inc. is indebted to the Company in the amount of $12,051. $12,051 lent by the Company to Entest Biomedical, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. As of June 30, 2015 the Company is indebted to BMSN in the amount of $19,701. $19,701 lent to the Company by Bio Matrix Scientific Group, Inc. is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. As of June 30, 2015 the Company is indebted to David R. Koos in the amount of $50. $50 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 8. COMMITMENTS AND CONTINGENCIES The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to the Company by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company’s parent and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month. On March 20, 2015 Regen Biopharma, Inc. agreed to sublease 199 square feet of laboratory space located at 5310 Eastgate Mall, San Diego, CA 92121 from Human BioMolecular Research Institute (“Sublease Agreement”). Pursuant to the terms of the Sublease Agreement Regen Biopharma, Inc. will pay rent of $400 per month to Human BioMolecular Research Institute (“HBRI”) . The term of the sublease shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. On June 1, 2015 Regen Biopharma, Inc. terminated its sublease with Human BioMolecular Research Institute On March 20, 2015 Regen Biopharma, Inc entered into a Research Agreement with HBRI wherein HBRI agreed to provide a variety of professional, scientific and technical services for the proper conduct of research by Regen Biopharma, Inc. and also to make available certain research equipment to Regen Biopharma, Inc. The term of the agreement shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. As consideration Regen Biopharma, Inc shall pay a monthly fee of $2,700 to HBRI over the term of the agreement. On June 1, 2015 Regen Biopharma, Inc. terminated the aforementioned agreement with Human BioMolecular Research Institute

Stockholders Equity

Stockholders Equity	9 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders Equity	NOTE 9. STOCKHOLDERS' EQUITY The stockholders' equity section of the Company contains the following classes of capital stock as June 30, 2015: Common stock, $ 0.0001 par value; 500,000,000 shares authorized: 113,525,096 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 100,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 30,000 shares issued and outstanding as of June 30, 2015 and 90,000,000 is designated Series A Preferred Stock of which 60,548,364 shares are outstanding as of June 30, 2015. The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. Series AA Preferred Stock On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,000). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION ("Certificate of Designations") with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as "Series A Preferred Stock" (hereinafter referred to as "Series A Preferred Stock"). The Board of Directors of the Company have authorized 90,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one . Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

Stock Transactions

Stock Transactions	9 Months Ended
	Jun. 30, 2015
Notes to Financial Statements
Stock Transactions	NOTE 10. STOCK TRANSACTIONS Common Stock On April 14, 2015 the Company issued 1,428, 571 of its common shares in satisfaction of $40,000 of convertible indebtedness. On May 12, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness. On May 18, 2015 the Company issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness. On May 19, 2015 the Company issued 1,785,714 of its common shares in satisfaction of $50,000 of convertible indebtedness. Series A Preferred Stock On April 14, 2015 the Company issued 1,428, 571 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $40,000 face value convertible note issued by the Company. On May 19, 2015 the Company issued 200,000 of its shares of Series A Preferred Stock as consideration for services rendered by nonemployees. On May 19, 2015 the Company issued 1,785,714 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $50,000 face value convertible note issued by the Company.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 11. SUBSEQUENT EVENTS On July 1, 2015 the Company issued 412,242 of its shares of common stock as consideration for services rendered by a nonemployee.

Organization and Summary of S17

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
USE OF ESTIMATES	B. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CASH EQUIVALENTS	C. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
PROPERTY AND EQUIPMENT	D. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	E. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
INCOME TAXES	F. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	G. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.
ADVERTISING	H. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the three months ended June 30, 2015 and $0 for the three months ended June 30, 2014.

Notes Payable and Convertible18

Notes Payable and Convertible Notes Payable (Tables)	9 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	June 30, 2015 September 30, 2014 Bio Matrix Scientific Group, Inc. (Note 7) 19,701 90,000 David Koos ( Notes7) 50 30,168 Bio Technology Partners Business Trust 84,000 0 Notes payable $ 103,751 $ 120,168

Notes Receivable (Tables)

Notes Receivable (Tables)	9 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Notes Receivable	June 30, 2015 September 30, 2014 Entest Biomedical, Inc. (Note 7) $ 12,051 $ 10,422 Notes Receivable $ 12,051 $ 10,422

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets	Deferred tax assets: Net operating tax carry forwards $ 4,036,834 Other -0- Gross deferred tax assets 4,036,834 Valuation allowance (4,036,834 ) Net deferred tax assets $ -0-

Organization and Summary of S21

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015
Accounting Policies [Abstract]
Advertising expenses	$ 0	$ 0
Valuation allowance			100.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		38 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss since inception	$ (1,562,371)		$ (166,021)	$ (10,594,463)	$ (561,751)	$ (11,873,041)
Issuance of convertible debt	$ 775,000	$ 775,000	$ 90,000

Notes Payable and Convertible23

Notes Payable and Convertible Notes Payable - Notes Payable (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Debt Disclosure [Abstract]
Bio Matrix Scientific Group, Inc. (Note 7)	$ 19,701	$ 90,000
David Koos ( Notes7)	50	30,168
Bio Technology Partners Business Trust	84,000	0
Notes payable	$ 103,751	$ 120,168

Notes Payable and Convertible24

Notes Payable and Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Sep. 30, 2014
Lent by Bio Matrix Scientific Group, Inc.	$ 19,701			$ 90,000
Interest rate per annum	10.00%
Lent by David Koos	$ 50			30,168
Lent by Bio Technology Partners Business Trust	84,000			$ 0
Face value of convertible notes issued	882,686
Cash consideration for issued notes	775,000	$ 775,000	$ 90,000
Satisfaction of existing indebtedness	$ 107,686
Interest rate per annum payable quarerly	10.00%
Discount to lowest trading price	65.00%
Common shares issued upon conversion of notes payable	31,539,262
Series A preferred shares issued upon conversion of notes payable	31,538,862
Derivative liability	$ 2,368,685
Convertible notes, aggregate face value	$ 90,000
Price per share	$ .03
Shares issued in satisfaction of convertible notes payable	3,214,285
Aggregate derivative liability (Black-Scholes pricing)	$ 350,666
Series A Preferred Stock
Shares issued in satisfaction of convertible notes payable	3,214,285
Bio Matrix Scientific Group, Inc
Lent by Bio Matrix Scientific Group, Inc.	$ 19,701
Interest rate per annum	10.00%
David Koos
Interest rate per annum	15.00%
Lent by David Koos	$ 50
Bio Technology Partners Business Trust
Interest rate per annum	10.00%
Lent by Bio Technology Partners Business Trust	$ 84,000

Notes Receivable - Notes Receiv

Notes Receivable - Notes Receivable (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Receivables [Abstract]
Entest Biomedical, Inc. (Note 7)	$ 12,051	$ 10,422
Note Receivable	$ 12,051	$ 10,422

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2015	Sep. 30, 2014
Receivables [Abstract]
Entest Biomedical note receivable	$ 12,051	$ 10,422
Interest rate on note receivable	10.00%

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details)	Jun. 30, 2015USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 4,036,834
Other	0
Gross deferred tax assets	4,036,834
Valuation allowance	(4,036,834)
Net deferred tax assets	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - Jun. 30, 2015 - USD ($)	Total
Income Tax Disclosure [Abstract]
Deferred Tax Asset	$ 4,036,834
Net operating loss carry forwards	$ 11,873,041
Federal corporate rate	34.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	35 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Sep. 30, 2014
Related Party Transactions [Abstract]
Capital contributions from related party		$ 728,658
Common shares issued to BMSN		50,010,000
Value of shares issued to BMSN		$ 20,090
Monthly rent payable to Entest	$ 5,000
Amount due from related party (ENTB)	$ 12,052	12,052
Interest rate per annum	10.00%
Amount payable to related party (BMSN)	$ 19,701	19,701	$ 90,000
Amount due to company CEO	$ 50	$ 50

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2015	Mar. 20, 2015
Commitments and Contingencies Disclosure [Abstract]
Sublease, rent payable		$ 5,000
Monthly sublease fee to HBRI		$ 400
Monthly research agreement fee	$ 2,700

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	3 Months Ended
	Jun. 30, 2015	Sep. 30, 2014
Common stock, Par value	$ 0.0001	$ 0.0001
Common stock, authorized	500,000,000	500,000,000
Common stock issued and outstanding	113,525,096	51,907,917
Preferred stock, par value	$ 0.0001	$ .0001
Preferred stock, authorized	100,000,000	5,000,000
Series A Preferred Stock
Preferred stock, par value	$ 0.0001
Preferred stock, authorized	90,000,000	0
Preferred stock, shares issued and outstanding	60,548,364	0
Preferred stock, shares outstanding	60,548,364	0
Preferred stock, non-cumulative cash dividends	$ .01
Series AA Preferred Stock
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized	600,000	600,000
Preferred stock, shares issued and outstanding	30,000	0
Preferred stock, shares outstanding	30,000	0

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	May. 19, 2015	May. 18, 2015	May. 12, 2015	Apr. 14, 2015
Common Stock
Shares issued	$ 1,785,714	$ 500,000	$ 500,000	$ 1,428,571
Total debt converted	50,000	$ 15,000	$ 15,000	40,000
Series A Preferred Stock
Shares issued	1,785,714			1,428,571
Total debt converted	$ 50,000			$ 40,000
Shares issued for services	200,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Jul. 01, 2015shares
Subsequent Events [Abstract]
Common stock as consideration for services	412,242